Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alocyte
- Development stage
- Phase 1
- Lead developer
- Alimorad Farshchian
- Modality
- Cell Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intraarticular
01
Overview
Alocyte is a cellular therapeutic product derived from human umbilical cord blood, consisting of cord blood plasma and mononuclear cells. Developed by Dr. Alimorad Farshchian, it is currently being evaluated in Phase 1 clinical trials for the treatment of facetogenic back pain. The product is minimally manipulated and contains a heterogeneous population of cellular components, including nucleated cells, exosomes, and various cytokines. Alocyte demonstrates robust expression of repair-oriented cytokines such as RANTES (CCL5) and Osteopontin, as well as pro-angiogenic factors like Angiostatin. The treatment is administered via intra-articular facet injection and aims to provide a regenerative approach by reducing local inflammation and promoting tissue repair within the facet joints, addressing the underlying pathogenic mechanisms of back pain.
- Brand names
- Alocyte
- Other names
- cord blood plasma plus mononuclear cells
Beyond the preview
Go deeper on Alocyte.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alocyte.